Enhanced Nanovectors for Targeted Delivery and Monitoring

The present invention relates to improved nanovectors for delivering active substances in the body, featuring enhanced targeting capabilities, controlled release, and non-invasive monitoring. These advancements address the limitations of existing nanovectors, providing more efficient and safer treatments.

The original patent disclosed nanovectors with polysiloxane-based nanoparticles for delivering active substances. However, these nanovectors had limitations in terms of targeting specific cells or tissues, controlled release of the active substance, and monitoring the delivery process. The new inventive concept addresses these limitations by introducing targeting moieties, stabilizing agents, and controlled release mechanisms, enabling more efficient and safer treatments.

The new inventive concept comprises a system for targeted delivery of active substances, featuring a nanovector with a polysiloxane-based nanoparticle having a mean diameter of less than 10 nm. The nanovector is conjugated with a targeting moiety specific to a predetermined cell type or tissue, ensuring targeted delivery. Additionally, the nanovector may include a stabilizing agent to prevent aggregation in physiological environments. The controlled release of the active substance is achieved through the design of the nanovector, which can be monitored using non-invasive imaging techniques. The inventive concept also encompasses methods for enhancing the efficacy of chemotherapy, treating cancer, and monitoring the delivery of active substances.

The new inventive concept introduces novel features, including targeting moieties, stabilizing agents, and controlled release mechanisms, which are not present in the original patent. These advancements provide a significant improvement over existing nanovectors, enabling more efficient and safer treatments. The combination of these features and their implementation in the inventive concept constitutes a non-obvious improvement over the prior art.

Alternative embodiments of the inventive concept may include varying the type and size of the polysiloxane-based nanoparticle, using different targeting moieties or stabilizing agents, or incorporating additional components to enhance the delivery and monitoring of active substances. These variations can be tailored to specific applications, such as treating different types of cancer or delivering various active substances.

The enhanced nanovectors of the present invention have significant commercial potential in the pharmaceutical industry, particularly in the areas of cancer treatment and targeted drug delivery. The ability to provide more efficient and safer treatments can lead to improved patient outcomes and reduced healthcare costs. The market for targeted drug delivery is expected to grow significantly in the coming years, and the present invention is well-positioned to capitalize on this trend.